<DOC>
	<DOCNO>NCT01812018</DOCNO>
	<brief_summary>The purpose exploratory phase II study ass effectiveness safety profile EndostarÂ® ( Recombinant Human Endostatin Injection ) plus Gemcitabine Docetaxel treatment soft tissue sarcoma patient pulmonary metastasis .</brief_summary>
	<brief_title>Endostar + GT Pulmonary Metastases Soft Tissue Sarcoma</brief_title>
	<detailed_description>Anticipated 30 subject enrol receive Endostar , Gemcitabine Docetaxel . Endostar dosage 7.5 mg/m2 administer Day 1-14 cycle . Gemcitabine ( 1000 mg/m2 ) administer Day 1 Day 8 cycle . Docetaxel ( 75 mg/m2 ) administer Day 2 cycle . An individual cycle therapy define 3-week ( 21-day ) period . Cycles repeat every 3 week . Multiple cycle may administer subject PD maximum 6 cycle . Time-to-progression ( TTP ) assess use Kaplan Meier method . Overall response rate ( ORR ) well individual category response ( CR , PR , SD , PD ) determine use RECIST ( v1.1 ) . Evaluation 1- 2-year overall survival also perform . Safety measure record use NCI-CTCAE ( v4.0 ) .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Endostatins</mesh_term>
	<criteria>Age 1870 year , male female . ECOG performance status &lt; =2 . Life expectancy &gt; = 3 month . Histologically cytologically confirm soft tissue sarcoma ( GIST exclude ) . Patients must prior anthracycline and/or ifosfamide either adjuvant metastatic set one regimen . At least one measurable pulmonary metastasis tumor lesion accord RECIST 1.1 criterion . Laboratory value : Hemoglobin ( Hb ) &gt; = 90 g/L blood transfusion within 14 day , Absolute neutrophil count ( ANC ) &gt; = 1.5 x 10^9/L , Platelet ( Plt ) &gt; = 80 x 10^9/L , Total Bilirubin ( Tbil ) = &lt; 1.5 x upper limit normal ( ULN ) , Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) = &lt; 2.5 x ULN = &lt; 5 x ULN liver metastasis present , Serum creatinine ( Cr ) = &lt; 1.0 x ULN , Endogenous creatinine clearance ( Ccr ) &gt; 50 mL/min ( CockcroftGault ) . Women child bear potential must negative serum urine pregnancy test within 7 day enrollment willing use effective contraception study 8 week last IMP administration . Willingness participate study sign inform consent form . Females pregnant breastfeed Childbearing potential unwilling use effective contraception . Prior therapy Gemcitabine , Docetaxel Endostar . Subjects participate clinical trial within 4 week enrollment . Accompanied rapid progress organ invasion , e.g.lesion area great one half liver lung liver dysfunction . Uncontrolled central nervous system disorder psychiatric illness . Current , serious , clinically significant cardiac arrhythmia , symptomatic congestive heart failure , myocardial infarction enrollment . Patients abnormal bone marrow function : ANC &lt; 1.5 x 10^9/L , Plt &lt; 75 x 10^9/L , Hb &lt; 90g/L . Patients renal dysfunction : Cr &gt; 1.5 x ULN . Patients liver dysfunction : Tbil &gt; 1.5 x ULN . Uncontrolled brain metastasis . Unwillingness inability comply study protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Soft Tissue Sarcoma</keyword>
	<keyword>Pulmonary metastasis</keyword>
</DOC>